Latest News

Mitchel Shiffman, MD | Credit: Bon Secours
AHFIRM: Phase 2b Data Shows Promise for Larsucosterol in Alcohol-Associated Hepatitis

June 14th 2024

Despite missing the primary endpoint among the global study population, additional analyses of participants from the US revealed significant impacts on mortality reduction with larsucosterol.

Man-Fung Yuen, MD, PhD, DSc | Credit: ResearchGate
Imdusiran Reduces HBsAg, Maintains Response After End of Treatment in Phase 2a Trials

June 12th 2024

FDA black and white logo | Credit: US Food and Drug Administration
FDA Grants Accelerated Approval to Elafibranor (Iqirvo) for PBC

June 10th 2024

Rohit Loomba, MD, MHSc | Credit: UC San Diego Health
SYNERGY-NASH: Tirzepatide, a GIP/GLP-1 RA, Resolves MASH Without Worsening Fibrosis

June 8th 2024

Eric Lawitz, MD | Credit: UT Health San Antonio
Bemnifosbuvir, Ruzasvir Combination Shows 97% SVR12 Rate in Phase 2 Trial for HCV

June 7th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.